Insilico UAE AI Drug Discovery Deal

🔑 Enhanced Key Takeaways

• •The agreement is a formal Memorandum of Understanding (MoU) signed at World Health Expo (WHX) 2026 in Dubai between EDE's Dr. Fatima Al Kaabi and Insilico's Dr. Alex Aliper.
• •Insilico has operated an AI and quantum computing R&D center in Abu Dhabi since February 2023, collaborating with UAE universities like MBZUAI, Khalifa University, NYU Abu Dhabi, and UAE University.
• •The InSilico Medicine project leverages generative AI and deep learning to simulate drug efficacy digitally, targeting areas like oncology and fibrosis while aligning with UAE's biotechnology localization goals.
• •Insilico showcased the partnership at WHX 2026 with a joint booth at South Hall S19J30, highlighting real-world AI drug discovery applications.

🛠️ Technical Deep Dive

• •Pharma.AI platform: Proprietary end-to-end AI suite used in the partnership for accelerating translational research from AI-generated candidates to clinical applications.
• •Generative AI and deep learning integration: Employed in the InSilico Medicine project to create advanced digital models for simulating drug efficacy prior to physical production, reducing R&D timelines and costs.
• •LFM2-2.6B-MMAI model (recent partnership with Liquid AI): 2.6B-parameter lightweight foundation model trained on Insilico's MMAI Gym with 1,000+ benchmarks; outperforms larger models like GPT-5.1 in affinity prediction (2.5M measurements across 689 targets), chemical reasoning (FGBench), and retrosynthesis (ChemCensor); designed for on-premise deployment.

🔮 Future ImplicationsAI analysis grounded in cited sources

⏳ Timeline